Seminoma staging

Jump to navigation Jump to search

Seminoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Seminoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

TNM
Stage Grouping

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Treatment - Stage I
Treatment - Stage II
Treatment - Stage III
Treatment - Recurrent

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Seminoma staging On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Seminoma staging

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Seminoma staging

CDC on Seminoma staging

Seminoma staging in the news

Blogs on Seminoma staging

Directions to Hospitals Treating Seminoma

Risk calculators and risk factors for Seminoma staging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Overview

Staging

The staging for testicular seminoma is performed according to the TNM system with staging groupings. It can be remembered in its abbreviated form as:[1]

  • Stage I: confined to testis, epididymis, spermatic cord, scrotum
  • Stage II: lymph nodes involved but no distant metastases, and serum tumor markers are not very high
  • Stage III: distant metastases or moderately high serum tumor markers

The American Joint Committee on Cancer (AJCC) includes serum tumor marker levels in the stages for germ cell tumors, including seminoma. S describes the levels of serum tumour markers in the blood after orchiectomy. The serum tumor markers measured are alpha-fetoprotein (AFP), human chorionic gonadotropin (HCG), and lactate dehydrogenase (LDH).[2]

S Serum tumor marker levels
SX Tumor marker levels are not available or have not been measured.
S0 Tumor marker levels are normal.
S1 All tumor marker levels are above normal.
  • AFP is less than 1,000 ng/mL.
  • HCG is less than 5,000 mIU/mL.
  • LDH is less than 1.5 times the upper limit of the normal range.
S2 At least one tumor marker level is high.
  • AFP is between 1,000 and 10,000 ng/mL.
  • HCG is between 5,000 and 50,000 mIU/mL.
  • LDH is 1.5–10 times the upper limit of the normal range.
S3 At least one tumor marker level is very high.
  • AFP is higher than 10,000 ng/mL.
  • HCG is higher than 50,000 mIU/mL.
  • LDH is more than 10 times the upper limit of the normal range.

TNM Classification for Seminoma

TNM stands for tumor, nodes, and metastasis. TNM staging describes:[1]

  • size and extent of the primary tumor
  • number and location of any regional lymph nodes infiltrated by tumor cells
  • whether the cancer metastasized to distant part of the body
TNM Classification Definition
Primary Tumor (T)
TX Primary tumor cannot be assessed (orchiectomy not performed)
T0 No evidence of primary tumor
Tis Intratubular germ cell neoplasia (carcinoma in situ)
T1 *Tumor limited to testis and epididymis
T3 Tumor involves any of the ipsilateral pleural surfaces, with at least one of the following:
  • invasion of the endothoracic fascia
  • invasion into mediastinal fat
  • solitar tumor invading soft tissues of the chest wall
  • non-transmural involvement of the pericardium

T3 describes mesothelioma that is locally advanced, but potentially resectable

T4 Tumor involves any of the ipsilateral pleural surfaces, with at least one of the following:

T4 describes mesothelioma that is locally advanced, but unresectable

Regional Lymph Nodes (N)
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastasis
N1 Metastasis in either or both the ipsilateral bronchopulmonary lymph nodes and the hilar lymph nodes.
  • Bronchopulmonary lymph nodes are within the lungs.
  • Hilar lymph nodes are near where the bronchus enters the lung.
N2 Metastasis in ipsilateral subcarinal lymph nodes and in either the internal mammary lymph nodes or mediastinal lymph nodes on the same side.

OR
Metastasis in subcarinal lymph nodes or in either the internal mammary lymph nodes or mediastinal lymph nodes on the same side of the chest as the cancer.

  • Subcarinal lymph nodes are below the trachea.
  • Internal mammary lymph nodes are around the sternum.
  • Mediastinal lymph nodes are in the mediastinum.
N3 Metastasis in the contralateral mediastinal lymph nodes, internal mammary lymph nodes, or hilar lymph nodes and in either the supraclavicular lymph node or scalene lymph nodes on the ipsilateral or contralateral side.

OR
Metastasis in the contralateral mediastinal, internal mammary, or hilar lymph nodes or in either the supraclavicular or scalene lymph nodes on the ipsilateral or contralateral side.

  • Supraclavicular lymph nodes are located above the clavicle.
  • Scalene lymph nodes are located at the base of the neck.
Distant Metastasis (M)
M0 No distant metastasis
M1 Distant metastasis

References

  1. 1.0 1.1 Testicular cancer staging. Dr Marcin Czarniecki and A.Prof Frank Gaillard et al. Radiopaedia 2016. http://radiopaedia.org/articles/testicular-cancer-staging. Accessed on February 26, 2016
  2. Staging testicular cancer. Canadian cancer society 2016. http://www.cancer.ca/en/cancer-information/cancer-type/testicular/staging/?region=on. Accessed on February 26, 2016

Template:WH Template:WS